These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644 [TBL] [Abstract][Full Text] [Related]
6. TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/ Twist1 Pathway in Non-Small-Cell Lung Carcinoma. Li Y; Bai M; Xu Y; Zhao W; Liu N; Yu J Cell Physiol Biochem; 2018; 50(5):2004-2016. PubMed ID: 30404076 [TBL] [Abstract][Full Text] [Related]
7. ETS1 regulates Twist1 transcription in a Kras Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489 [TBL] [Abstract][Full Text] [Related]
8. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Jin HO; Hong SE; Woo SH; Lee JH; Choe TB; Kim EK; Noh WC; Lee JK; Hong SI; Kim JI; Park IC Cell Death Dis; 2012 Jun; 3(6):e319. PubMed ID: 22673193 [TBL] [Abstract][Full Text] [Related]
9. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242 [TBL] [Abstract][Full Text] [Related]
10. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381 [TBL] [Abstract][Full Text] [Related]
11. Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC). Gorgisen G; Ozes D; Pehlivanoglu S; Erdogan A; Dertsiz L; Ozbilim G; Ozbudak IH; Savas B; Ozes ON Exp Lung Res; 2013 Nov; 39(9):387-98. PubMed ID: 24117170 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of twist and N-cadherin expression in NSCLC. Hui L; Zhang S; Dong X; Tian D; Cui Z; Qiu X PLoS One; 2013; 8(4):e62171. PubMed ID: 23626784 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Twist1-mediated invasion by Chk2 promotes premature senescence in p53-defective cancer cells. Nayak D; Kumar A; Chakraborty S; Rasool RU; Amin H; Katoch A; Gopinath V; Mahajan V; Zilla MK; Rah B; Gandhi SG; Ali A; Kumar LD; Goswami A Cell Death Differ; 2017 Jul; 24(7):1275-1287. PubMed ID: 28498365 [TBL] [Abstract][Full Text] [Related]
14. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779 [TBL] [Abstract][Full Text] [Related]
15. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702 [TBL] [Abstract][Full Text] [Related]
16. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. Pallier K; Cessot A; Côté JF; Just PA; Cazes A; Fabre E; Danel C; Riquet M; Devouassoux-Shisheboran M; Ansieau S; Puisieux A; Laurent-Puig P; Blons H PLoS One; 2012; 7(1):e29954. PubMed ID: 22272264 [TBL] [Abstract][Full Text] [Related]
17. Metastasis-associated in colon cancer-1 promotes vasculogenic mimicry in gastric cancer by upregulating TWIST1/2. Wang L; Lin L; Chen X; Sun L; Liao Y; Huang N; Liao W Oncotarget; 2015 May; 6(13):11492-506. PubMed ID: 25895023 [TBL] [Abstract][Full Text] [Related]
18. Positive feedback loop of lncRNA LINC01296/miR-598/Twist1 promotes non-small cell lung cancer tumorigenesis. Xu L; Wei B; Hui H; Sun Y; Liu Y; Yu X; Dai J J Cell Physiol; 2019 Apr; 234(4):4563-4571. PubMed ID: 30240003 [TBL] [Abstract][Full Text] [Related]
19. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006 [TBL] [Abstract][Full Text] [Related]
20. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]